Reimbursement scheme Forxiga®

General information

The Reimbursement Solution TerugBetaalRegeling (TBR) of Forxiga® (dapagliflozine) 10 mg for patients with diabetes type 2, WITHOUT a very high risk of cardiovascular disease AND who are not eligible for the pre-existing reimbursement of the health insurer (in combination with metformin and/or SU), will be continued. The end date for this TBR for this group of patients has not yet been determined.

Type 2 diabetes patients WITH a very high risk on cardiovascular disease are covered by the regular reimbursement of the health insurance. Very high risk is defined as:
• established cardiovascular disease; and/or
• all forms of heart failure, regardless of ejection fraction
• chronic kidney disease with
- eGFR ≥ 60 ml/min/ 1.73 m2 with ACR > 30 mg/mmol
- eGFR 45-59 ml/min/ 1.73 m2 with ACR > 3 mg/mmol
- eGFR 10-44 ml/min/ 1.73 m2

^{(NL-10246 Prod 10.2022)}

For a complete reimbursment overview of Forxiga® (dapagliflozine) 10 mg, clickhere.

For a digital reimbursement guide of Forxiga® (dapagliflozine) 10 mg, click here.

Dose	Forxiga® 10mg
Type	Tablets
Active ingredient	DAPAGLIFLOZINE

Reimbursement

Conditions

Declarations of Forxiga® (dapagliflozine) 10 mg for patients with type 2 diabetes WITHOUT a very high risk of cardiovascular disease AND who are not eligible for the pre-existing regular reimbursement of the health insurer (in combination with metformin and/or SU), with an issue date from 1 July 2019 can be submitted to TBR Nederland.

Declarations of Forxiga® (dapagliflozine) 10 mg for patients WITH type 2 diabetes and very high risk of cardiovascular disease, with an issue date between July 1, 2019 and September 1, 2021, have expired and can NO longer be submitted. Issues from September 1, 2021 for this group of patients will be fully reimbursed by the health insurer.

Who can submit a claim

Patients or their caregiver can claim the Personal Contribution for Forxiga® (dapagliflozine) 10mg online or by mail.
Pharmacists can only claim this medicine online on behalf of the patient.

From when till when can you submit a claim

Declarations advanced by the pharmacy can only be submitted to TBR Nederland up to 6 months after issued. For this reimbursement scheme no closing date has been determined yet.